Tails - my opinion is that he was referring to the very specific cancer diagnosis of the participants in the other trial. The trial chose cancer specific to best preclinical results, and allowed nonterminal patients in - so results will be better, sooner. Ctix set very high standards with the diagnostic diversity and terminal conditions of participants in this phase one. But doing so will allow for greater diversity of phase IIs and piggyback 1Bs.